I’m an ex-pharma rep too. I agree with what you’re saying but I will add that certain products are going to be successful regardless. People who sold Viagra and Lipitor didn’t have to work very hard to convince doctors about the coverage, efficacy, and safety of their drugs. (I know it wasn’t that simple, but compared with your average drug it pretty much was) They were game changers basically right out of the gate. I think Leronlimab, for Covid-19, will be the same. The science and the need will supersede any marketing or salesmanship efforts. But for HIV, I see the effort being much more impacted by the sales team, marketing messaging, insurance coverage, and other market dynamics like you mention. It should end up as a game changer in HIV but it will happen in more of the traditional pharma way versus a solution to a worldwide pandemic. (I don’t mean to minimize HIV as a worldwide problem, by the way. Just that the coronavirus moment we are in has the world by the you-know-whats at the moment)